肝后性门静脉高压症的诊断与治疗

刘磊; 叶青; 韩涛

doi:10.3969/j.issn.1001-5256.2019.01.004

肝后性门静脉高压症的诊断与治疗

DOI: 10.3969/j.issn.1001-5256.2019.01.004

天津医科大学三中心临床学院天津市第三中心医院肝内科天津市人工细胞重点实验室天津市肝胆疾病研究所卫生部人工细胞工程技术研究中心

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1959
- HTML全文浏览量: 45
- PDF下载量: 483
- 被引次数: 0
出版历程
- 出版日期: 2019-01-20

Diagnosis and treatment of post-hepatic portal hypertension

The Third Central Clinical College of Tianjin Medical University, Department of Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cells, Tianjin Institute of Hepatobiliary Disease, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin 300170, China

摘要

摘要: 肝后性门静脉高压症是指肝外肝静脉梗阻,肝外肝静脉与右心之间的肝血流出道受阻引起的门静脉高压。常见病因有布加综合征、右心衰竭及缩窄性心包炎等。随着医学的进一步发展,近年来对于这些疾病的诊断和治疗都取得了长足的进步。
- 高血压,门静脉 /
- Budd-Chiari综合征 /
- 心力衰竭 /
- 心包炎,缩窄性 /
- 诊断 /
- 治疗
Abstract: Post-hepatic portal hypertension refers to portal hypertension caused by the obstruction of liver blood flow between the extrahepatic liver vein and the right heart due to the obstruction of the extrahepatic liver vein.Common etiologies include Budd-Chiari syndrome, right heart failure, and constrictive pericarditis.With the development of medicine, great progress has been made in the diagnosis and treatment of these diseases in recent years.
- hypertension, portal /
- budd-chiari syndrome /
- heart failure /
- pericarditis, constrictive /
- diagnosis /
- therapy

HTML全文

参考文献(47)

[1]JAIME B, YASUKO I.The portal hypertension syndrome:etiology, classification, relevance, and animal models[J].Hepatol Int, 2018, 12 (Suppl 1) :s1-s10.

[2]OLIVER TI, JOHN S.Hypertension, Portal.Stat Pearls[M].Treasure Island (FL) :Stat Pearls Publishing, 2018.

[3]Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics.Diagnosis and treatment guidelines for aberrant portal hemodynamics:The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan[J].Hepatol Res, 2017, 47 (5) :373-386.

[4]MARTENS P, NEVENS F.Budd-Chiari syndrome[J].United Eur Gastroenterol, 2015, 3 (6) :489-500.

[5]Chinese Medical Association Chinese Society of Radiology (CSR) Interventional Group.Guidelines of the interventional treatment for Budd-Chiari syndrome[J].Chin J Radiol, 2010, 44 (4) :345-349. (in Chinese) 中华医学会放射学分会介入学组.布加综合征介入诊疗规范的专家共识[J].中华放射学杂志, 2010, 44 (4) :345-349.

[6]Expert Committee on Vena Cava Obstruction, Specialized Committee of Endovascology, Chinese Medical Doctor Association.Expert consensus on the classification of subtypes in Budd-Chiari syndrome[J].J Clin Hepatol, 2017, 33 (7) :1229-1235. (in Chinese) 中国医师协会腔内血管学分会腔静脉阻塞专家委员会.布-加综合征亚型分型的专家共识[J].临床肝胆病杂志, 2017, 33 (7) :1229-1235.

[7]QI X, HAN G, GUO X, et al.Review article:The aetiology of primary Budd-Chiari syndrome-differences between the West and China[J].Aliment Pharmacol Ther, 2016, 44 (11-12) :1152-1167.

[8]PLESSIER A, RAUTOU PE, VALLA DC.Management of hepatic vascular diseases[J].J Hepatol, 2012, 56 (Suppl 1) :s25-s38.

[9]LANGLET P, ESCOLANO S, VALLA D, et al.Clinicopathological forms and prognostic index in Budd-Chiari syndrome[J].J Hepatol, 2003, 39 (4) :496-501.

[10]VALLA DC.Primary Budd-Chiari syndrome[J].J Hepatol, 2009, 50 (1) :195-203.

[11]van WETTERE M, BRUNO O, RAUTOU PE, et al.Diagnosis of Budd-Chiari syndrome[J].AbdomRadiol (NY) , 2018, 43 (8) :1896-1907.

[12]WANG ZG.Wang Zhonghao vascular surgery[M].Hangzhou:Zhejiang Science and Technology Press, 2010:629-630. (in Chinese) 汪忠镐.汪忠镐血管外科学[M].杭州:浙江科学技术出版社, 2010:629-630.

[13]ZHOU P, REN J, HAN X, et al.Initial imaging analysis of Budd-Chiari syndrome in Henan province of China:most cases have combined inferior vena cava and hepatic veins involvement[J].PLo S One, 2014, 9 (1) :e85135.

[14]FLOR N, ZUIN M, BROVELLI F, et al.Regenerative nodules in patients with chronic Budd-Chiari syndrome:a longitudinal study using multiphase contrast-enhanced multidetector CT[J].Eur J Radiol, 2010, 73 (3) :588-593.

[15]de GOTTARDI A, BERZIGOTTI A, BUSCARINI E, et al.Ultrasonography in liver vascular disease[J].Ultraschall Med, 2018, 39 (4) :382-405.

[16]ZHANG LM, ZHANG GY, LIU YL, et al.Ultrasonography and computed tomography diagnostic evaluation of Budd-Chiari syndrome based on radical resection exploration results[J].Ultrasound Q, 2015, 31 (2) :124-129.

[17]MARUYAMA H, YOKOSUKA O.Ultrasonography for noninvasive assessment of portal hypertension[J].Gut Liver, 2017, 11 (4) :464-473.

[18]LU L, XU K, HAN C, et al.Comparison of 3.0T MRI with 3DLAVA sequence and digital subtraction angiography for the assessment of accessory hepatic veins in Budd-Chiari syndrome[J].J MagnReson Imaging, 2017, 45 (2) :401-409.

[19]YANG C, LI C, ZENG M, et al.Non-contrast-enhanced MRangiography in the diagnosis of Budd-Chiari syndrome (BCS) compared with digital subtraction angiography (DSA) :Preliminary results[J].MagnReson Imaging, 2017, 36:7-11.

[20]GRUS T, LAMBERT L, GRUSOVA G, et al.Budd-Chiari Syndrome[J].Prague Med Rep, 2017, 118 (2-3) :69-80.

[21]European Association for the Study of the Liver.EASL clinical practice guidelines:Vascular diseases of the liver[J].J Hepatol, 2016, 64 (1) :179-202.

[22]de FRANCHIS R.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[23]SEIJO S, PLESSIER A, HOEKSTRA J, et al.Good long-term outcome of Budd-Chiari syndrome with a step-wise management[J].Hepatology, 2013, 57 (5) :1962-1968.

[24]PLESSIER A, SIBERT A, CONSIGNY Y, et al.Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome[J].Hepatology, 2006, 44 (5) :1308-1316.

[25]PAREKH J, MATEI VM, CANAS-COTO A, et al.Budd-Chiari syndrome causing acute liver failure:A multi-center case series[J].Liver Transpl, 2017, 23 (2) :135-142.

[26]DE GA, TREBICKA J, KLINGER C, et al.Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis[J].Liver Int, 2017, 37 (5) :694-699.

[27]TRIPATHI D, SUNDERRAJ L, VEMALA V, et al.Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome[J].Liver Int, 2017, 37 (1) :111-120.

[28]SHARMA S, TEXEIRA A, TEXEIRA P, et al.Pharmacological thrombolysis in Budd Chiari syndrome:A single centre experience andreview of the literature[J].J Hepatol, 2004, 40 (1) :172-180.

[29]SMALBERG JH, SPAANDER MV, JIE KS, et al.Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis[J].Thromb Haemost, 2008, 100 (6) :1084-1088.

[30]TRIPATHI D, MACNICHOLAS R, KOTHARI C, et al.Good clinical outcomes fol owing transjugular intrahepatic portosystemic stentshunts in Budd-Chiari syndrome[J].Aliment Pharmacol Ther, 2014, 39 (8) :864-872.

[31]HERNANDEZ-GUERRA M, TURNES J, RUBINSTEIN P, et al.PTFE-covered stents improve TIPS patency in BuddChiari syndrome[J].Hepatology, 2004, 40 (5) :1197-1202.

[32]MANCUSO A.An update on management of Budd-Chiari syndrome[J].Ann Hepatol, 2014, 13 (3) :323-326.

[33]PETERSEN BD, CLARK TW.Direct intrahepatic portocaval shunt[J].Tech Vasc Interv Radiol, 2008, 11 (4) :230-234.

[34]HATZIDAKIS A, GALANAKIS N, KEHAGIAS E, et al.Ultrasound-guided direct intrahepatic portosystemic shunt in patients with Budd-Chiari syndrome:Short-and long-term results[J].Interv Med Appl Sci, 2017, 9 (2) :86-93.

[35]MENTHA G, GIOSTRA E, MAJNO PE, et al.Liver transplantation for Budd-Chiari syndrome:A European study on 248 patients from 51 centres[J].J Hepatol, 2006, 44 (3) :520-528.

[36]SEGEV DL, NGUYEN GC, LOCKE JE, et al.Twenty years of liver transplantation for Budd-Chiari syndrome:A national registry analysis[J].Liver Transpl, 2007, 13 (9) :1285-1294.

[37]POTTHOFF A, ATTIA D, PISCHKE S, et al.Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms[J].Liver Int, 2015, 35 (8) :2042-2049.

[38]WESTBROOK RH, LEA NC, MOHAMEDALI AM, et al.Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation[J].Liver Transpl, 2012, 18 (7) :819-827.

[39]CHINNAKOTLA S, KLINTMALM GB, KIM P, et al.Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology[J].Transplantation, 2011, 92 (3) :341-345.

[40]KONSTAM MA, KIERNAN MS, BERNSTEIN D, et al.Evaluation and management of right-sided heart failure:A scientific statement from the american heart association[J].Circulation, 2018, 137 (20) :e578-e622.

[41]WELCH TD.Constrictive pericarditis:Diagnosis, management and clinical outcomes[J].Heart, 2018, 104 (9) :725-731.

[42]ADLER Y, CHARRON P, IMAZIO M, et al.2015 ESC Guidelines for the diagnosis and management of pericardial diseases:The task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) Endorsed by:The European Association for Cardio-Thoracic Surgery (EACTS) [J].Eur Heart J, 2015, 36 (42) :2921-2964.

[43]SYED FF, SCHAFF HV, OH JK.Constrictive pericarditis-a curable diastolic heart failure[J].Nat Rev Cardiol, 2014, 11 (9) :530-544.

[44]CHOWDHURY UK, SUBRAMANIAM GK, KUMAR AS, et al.Pericardiectomy for constrictivepericarditis:A clinical, echocardiographic, and hemodynamic evaluation of two surgical techniques[J].Ann Thorac Surg, 2006, 81 (2) :522-529.

[45]BERTOG SC, THAMBIDORAI SK, PARAKH K, et al.Constrictive pericarditis:Etiology and cause-specific survival after pericardiectomy[J].J Am Coll Cardiol, 2004, 43 (8) :1445-1452.

[46]LING LH, OH JK, SCHAFF HV, et al.Constrictive pericarditis in the modern era:Evolving clinical spectrum and impact on outcome after pericardiectomy[J].Circulation, 1999, 100 (13) :1380-1386.

[47]KOMODA T, FRUMKIN A, KNOSALLA C, et al.Child-Pugh score predicts survival after radical pericardiectomy for constrictive pericarditis[J].Ann Thorac Surg, 2013, 96 (5) :1679-1685.

施引文献

资源附件(0)

访问统计